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Designing nanomolar antagonists of
DC-SIGN-mediated HIV infection: ligand
presentation using molecular rods†
Stefania Ordanini,a Norbert Varga,a Vanessa Porkolab,bcd Michel The´paut,bcd
Laura Belvisi,ae Andrea Bertaglia,a Alessandro Palmioli,a Angela Berzi,f
Daria Trabattoni,f Mario Clerici,gh Franck Fieschibcd and Anna Bernardi*ae
DC-SIGN antagonists were designed combining one selective mono-
valent glycomimetic ligand with trivalent dendrons separated by a
rigid core of controlled length. The design combines multiple multi-
valency eﬀects to achieve inhibitors of HIV infection, which are active
in nanomolar concentration.
Carbohydrate–protein interactions in biological systems mostly
occur among multivalent partners. This increases the potency
of sugar ligands that in monovalent form would be too weak to
have biological relevance. To interfere with such interactions,
multivalent antagonists have been designed, which include a
variety of scaffolds.1 Potency enhancement in multivalent ligands
can result from different mechanisms, including clustering of
soluble partners (Fig. 1A), chelation (Fig. 1B) and statistical
rebinding (or proximity, Fig. 1C) effects, which can be exploited
to different degrees by different ligand/target pairs.2
The ability of a multivalent ligand to chelate (i.e. to bind
simultaneously) more than one binding site of a target critically
depends on the spacer separating the ligand subunits. The
design of eﬀective spacers requires a delicate balance between
rigidity, which favors association by decreasing the entropic
cost, and flexibility, which helps the ligand system to adapt to
the protein, being itself a flexible, dynamic target. Most systems
reported so far have been built using flexible spacers, which
are both synthetically more accessible, and more tolerant of
design imperfections.3,4
Together with the Pieters group, we have recently reported the
synthesis of rod-like rigid spacers 1–3 (Scheme 1 and Scheme SI-2 in
the ESI†) of variable length, based on phenylene-ethynylene units and
their incorporation into divalent ligands for P. aeruginosa lectin LecA.5
We now show how these rod-like spacers can be used in the modular
design of hexavalent dendrimers with a rigid core of defined length,
targeted against DC-SIGN, a tetrameric C-type lectin receptor of
dendritic cells hijacked by many pathogens in their infection cycle.6
Antagonists of DC-SIGN have been proposed as inhibitors of various
viral infections, including HIV, Ebola and Dengue.7
Fig. 1 (A) A multivalent ligand (red) clustering a soluble protein (blue); (B) a
multivalent ligand chelating a divalent protein; (C) a multivalent ligand
binding to a protein exploiting the statistical rebinding (proximity) eﬀect.
Scheme 1 Strategy for the design of the rod-based dendrimers.
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The general strategy we describe here to target DC-SIGN strives to
exploit both chelation and statistical rebinding eﬀects by spacing two
appropriate trivalent ligands in a controlled fashion, so as to achieve
eﬃcient bindingwith relatively low valency of the construct. The design
of thedendrimers (Scheme1) includes 4, amannose-basedmonovalent
ligand of moderate aﬃnity (0.3 mM) and good selectivity for DC-SIGN
over Langerin,8 and dendron 5, which presents three copies of 4 and is
equipped with an azido group at the focal point for conjugation to the
rods.9 Depending on the length of the rod spacer (see ESI†), the new
constructs were predicted to span the required distance for chelation of
contiguous binding sites in DC-SIGN (B4 nm).10 Additionally, dendron
5 has a PEG-like structure, which grants the flexibility required for
optimal adaptation.11 Controls bearing the lower aﬃnity mannoside 6
allowed assessing the role of themonovalent ligand in determining the
overall activity of the construct. Divalent structures were also synthe-
sized, either by direct conjugation of 4 and 6 to the rods, or using 7, to
aﬀord dimers of comparable length (Scheme 1). Analysis of the binding
eﬃciency and comparison of hexavalent and divalent structures
allowed dissecting the relative importance of chelation and statistical
rebinding for this interaction. Optimal combination of rod length,
valency and monovalent ligand yielded a hexavalent dendrimer which
inhibits DC-SIGN mediated transmission of HIV infection in nano-
molar concentrations. Here we report our results.
Dendron 59 and rods 1–35 were prepared as previously described.
A copper(I) catalyzed dipolar cycloaddition (CuAAC) between 5 and the
appropriate diynes 1–3 yielded hexavalent dendrimers of increasing
dimensions, bearing either 4 or 6 as the ligand (Table 1). Divalent
controls were synthesized using the same approach using ligands 7.4
and 7.6 (with a linker length equivalent to the length of the dendron
chain), or conjugating 4 and 6 directly to 3. The compounds prepared
are shown in Table 1. All compounds were water soluble (Z150 mM).
They were purified by either reverse phase chromatography
(C18 silica) or gel filtration (Sephadex LH-20) and characterized
by NMR and MS analysis. Details of the synthesis and char-
acterization are reported in the ESI.† Hexavalent dendrimers
8.4 and 8.6, known to operate only by statistical rebinding and
clustering effects,9 were used as reference.
The activity of all compounds was tested by SPR in the previously
established competition assay that measures their ability to inhibit
binding of theDC-SIGN extracellular domain (ECD) tomannosylated
bovine serum albumin (Man-BSA) immobilized onto the SPR sensor
surface.8 The results are shown in Fig. 2 and Table 2. Sensorgrams
and inhibition curves are collected in the ESI† (Fig. SI-7 and SI-8).
Clear trends are shown by the constructs bearing the lower activity
pseudo-dimannoside ligand 6 (Fig. 2, blue bars; Table 2, ligand 6
row). In the hexavalent series (8.6, 1.5.6, 2.5.6 and 3.5.6), aﬃnity and
relative inhibitory potency b12 increase regularly with the length of
the rod, reaching IC50 = 9 mM and b = 17 with 3.5.6 (Table 2).
Similarly, in the group of divalent ligands 1.7.6, 2.7.6 and 3.7.6
the IC50 values decrease regularly as the rod length increases and the
b-factor increases from 2 to 7 (Fig. 2, divalent rods, blue bars).
For these compounds, data also show an important eﬀect of the
length of the linker connecting the rod to the active ligand. The
short linker dimer 3.6 with an IC50 of 36 mM is twice as active as
the corresponding long linker derivative 3.7.6 (IC50 67 mM), as a
result of entropy loss associated with a long flexible linker.
Comparison of b-factors for hexavalent and divalent constructs
of a similar core reveals the positive eﬀect of the local increase
of ligand concentration generated by the trivalent dendron in
1.5.6, 2.5.6 and 3.5.6, which corresponds to an increase of the
relative potency by at least a factor of two. As expected, all
dendrimers bearing the higher aﬃnity monovalent ligand 4 are
Table 1 Structures of the tested pseudoglycodendrimers
Structure
Ligand 6 Ligand 4
1.5.6 1.5.4
2.5.6 2.5.4
3.5.6 3.5.4
1.7.6 1.7.4
2.7.6 2.7.4
3.7.6 3.7.4
3.6 3.4
8.6 8.4
Fig. 2 DC-SIGN inhibition activities of glycodendrimers bearing ligand 6 (blue
bars) or 4 (green bars). DC-SIGN (20 mM) and compounds at increasing
concentration were co-injected over a CM4 chip where Man-BSA (Mana1–
3[Mana1–6]Man-BSA, 15 trimannose residues, on average) has been immobilized.
IC50 are expressed as dendrimer concentration (mM).
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more active than the corresponding ones based on 6 (compare
blue bars and green bars in Fig. 2). In the divalent series 1.7.4,
2.7.4 and 3.7.4, activities and b-factors increase regularly with
the rod length. Again, optimal aﬃnity values are obtained with a
long rod and a short flexible linker (3.4, IC50 = 8 mM), indicating a
good preorganization of the antagonist.3 No apparent trend is
revealed in the hexavalent series (8.4, 1.5.4, 2.5.4 and 3.5.4): all
compounds show similar IC50 in the low mM range (Fig. 2, hexa-
valent rod panel) and similar b-factor (approximately 10, Table 2).
With an apparent IC50 of 5 mM, these compounds have achieved
the intrinsic aﬃnity of DC-SIGN ECD for the Man-BSA functiona-
lized surface, thus the lower limit of the assay. The inhibition
curves observed only mirror the interaction curve of the reporter
system, which has become limiting (Fig. SI-8, ESI†).
Selected compounds were therefore tested in a more sensitive
assay, using a cellular model of HIV-1 infection. B-THP-1 cells
expressing DC-SIGN were used as a model of DCs and inhibition
of trans infection of CD4+ T-lymphocytes was analyzed (see ESI†
for full method details). The results of these trans infection studies
(Fig. 3, top) showed a clear dose–response effect for all the
tested inhibitors 8.4, 1.5.4, 3.5.4, 3.7.4 and 3.4. An IC50 around
1 mM was confirmed for 8.4, as previously reported,9 and a
similar value was obtained for divalent 3.7.4. The hexavalent
elongated structures of 1.5.4 and 3.5.4 and the divalent short
linker version 3.4 display an activity improved by one order of
magnitude or more and dependent on the rod length and the
overall valency of the system. In a second set of experiments,
dose–response was measured at lower concentrations for 1.5.4,
3.5.4 and 3.4 (Fig. 3, bottom). Data fitting to 1 :1 hyperbolic decay
afforded IC50 values of 67 nM, 24 nM and 161 nM, respectively.
Thus, these experiments confirmed that also in the cellular model
inclusion of a rigid spacer at the dendrimer core has a strong
positive effect on the antagonist activity. Dendrimer 3.5.4 (IC50
24 nM) is 40 times more active than 8.4 and among the most
potent DC-SIGN antagonists reported.13 The data also confirm the
impressive activity of the divalent ligand 3.4, but, as in the SPR study,
suggest that higher local concentration of the ligand is beneficial to
effectively block the infection. It is worth noting that SPR assays are
performed using DC-SIGN solubilised in the medium and therefore
they measure effects derived also from the protein aggregation
mechanism (Fig. 1A). In contrast, in cellular studies the protein is
immobilized in the cell membrane. Nonetheless, both assays clearly
show that both the length of the rod and the overall valency of the
material have an influence on the IC50 values.
In order to interpret the results on a structural basis, the shape
and size of the ligands were simulated by molecular dynamics, using
the 6 series as models. For the sake of simplicity, the PEG chains on
the rods were replaced with methyl ethers. Starting structures were
obtained by simulated annealing and then subjected to multiple
StochasticDynamics (SD) simulation cycles for a total SD time ranging
from 125 to 150 ns (OPLSA-2005 force field, GB/SA water solvation
model; controls were synthesized also using an explicit water solvation
model, details are provided in the ESI†). Mannose is known to use O3
and O4 to coordinate the Ca2+ ion in the DC-SIGN binding site and
the distance between two adjacent sites in the tetrameric protein was
estimated to be at least 38 Å by SAXS.10 Thus, the potential of
multivalent compounds to simultaneously coordinate two Ca2+ sites
was evaluated by monitoring the distance between Man-O3 of two
distal sugar residues during the simulation. The time course of the
distances is shown in Fig. SI-1/SI-4 of the ESI.† Average values hdO3–O3i
and values at the maximum extension Max dO3–O3 are reported in
Table SI-1 (ESI†), together with the dendrimers’ gyration radius. The
simulations confirm that the hexavalent dendrimer 8.6 (Max dO3–O3
35.4 Å) is not likely to bridge between two DC-SIGN binding sites,
even at its maximum extension.9 All dendrimers that include a rod
at their core, even the shortest one 1, can comfortably reach across
in their most extended conformations. However, the flexibility of
the long linker in 1.7.6, 3.7.6 and 3.5.6 allows the sugars to fold over
the aromatic cores, producing much more compact conformations
that represent over 95% of the sampled population. Representative
folded conformations of 3.7.6 and 3.5.6 are shown in Fig. 4.
Table 2 IC50 values (mM, dendrimer concentration) of multivalent derivatives of 6 or 4 inhibiting binding of DC-SIGN ECD to immobilized Man-BSA
IC50 (mM) (b-factor)
a
Scaﬀold
Ligand Mono 8 1.5 2.5 3.5 1.7 2.7 3.7 3
6 901 (1) 39 (4) 34 (4) 25 (6) 9 (17) 295 (2) 175 (3) 67 (7) 36 (13)
4 271 (1) 5b (10) 6b (8) 7b (7) 5b (9) 61 (2) 34 (4) 19 (7) 8b (17)
a Valency corrected b-factor12 (relative inhibitory potency). b Lower limit of the assay was reached.
Fig. 3 Trans infection experiments. Compounds were tested at the con-
centrations indicated and compared with the eﬀect of the medium (MED).
Experiments were performed on CD4+ T-lymphocytes isolated from 3
diﬀerent healthy donors. The concentration of p24 in co-culture super-
natants reflects the level of infection. Values represent the mean SD (top)
8.4, 1.5.4, 3.5.4, 3.7.4, and 3.4 in the concentration range 1–50 mM;
(bottom) 1.5.4, 3.5.4 and 3.4 in the concentration range 0.01–10 mM.
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The most extended average structure was calculated for the short
linker dimer 3.6, which features Max dO3–O3 and hdO3–O3i of 43.3 Å
and 31.7 Å, respectively. Most importantly, 30% of the structures
sampled during the simulations display dO3–O3 larger than 35 Å and
are therefore likely to be productive as protein chelating agents.
This supports the notion that dimer 3.6 is optimally preorganized
for DC-SIGN binding. Indeed, docking it within two adjacent
binding sites of a DC-SIGN tetramer yielded a complex (Fig. 5)
that was stably bound during dynamic simulations performed
using an implicit GB/SA water model (25 ns). Similar complexes
generated for the long linker dimers 3.7.6 (Fig. SI-6B, ESI†) and
1.7.6 (Fig. SI-6C, ESI†) also showed stable chelation over the
course of 25 ns simulations, accompanied by extensive dynamics
of the flexible linkers.
It was recognized early on that multivalent presentations of native
ligands could improve recognition by DC-SIGN14 and the concept was
used with many diﬀerent constructs.1 It is still debated whether
designing ligands for accurate fitting of polyvalent targets is worth
the eﬀort, as compared to ‘‘brute force’’ high valency presentation of
weak ligands (often easily accessible: e.g.monosaccharides). Of course
this has implications beyond carbohydrate–protein interactions and
the final response will have to account also for additional considera-
tions, such as costs (siding against design) and regulatory problems
(siding against poorly controlled and ill characterized polyvalent
materials). Additionally, the optimal presentation format may vary
in different situations depending, most notably, on whether the
multivalent target is soluble or embedded in membranes, which
controls the occurrence of aggregation effects. It is well-established
and confirmed by the present study that the design of themonovalent
ligand has a measurable impact on the affinity of constructs of
moderate valence. Probably, the most important consequence of
monovalent ligand design is the ability to achieve selectivity.8 The
work described here shows that rod-like rigid spacers can be used to
control the size of multivalent constructs to match the target dimen-
sion, thus maximizing the impact of the system valency. Extended
spacers of ‘‘perfect’’ length as in 3.4 generate excellent divalent
binders. Addition of a flexible linker causes entropic loss upon
binding and reduces the activity (compare 3.4 and 3.7.4 in Fig. 3,
top). However, inclusion of even a slight increase in local concen-
tration of the ligand, such as that provided by the two trivalent
dendrons in 3.5.4, can make up for under-optimization of the linker
and is a good trade-off between the two concepts of fitting by design
and affinity by avidity.
The design of DC-SIGN antagonists is actively explored as an
approach to blockmucosal pathogens that are still a challenge for the
development of vaccines. Compound 3.5.4 was designed as a rational
combination of three elements: an eﬀective (and selective) mono-
valent ligand, a rigid core of appropriate length and two trivalent
dendrons. The material obtained inhibits DC-SIGN mediated HIV
transmission with an IC50 in the nM range, a result that compares
well with known DC-SIGN antagonists (polymers, dendrimers
or gold nanoparticles) of much higher valency.13a,c,d
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Fig. 4 (A) Structures of the most represented conformations sampled
during the dynamic simulations of 3.7.6. Two types of folds (type I and type
II) are observed. (B) Representative structures from the simulation of 3.5.6:
type II folds are favored.
Fig. 5 Docked complex of divalent ligand 3.6 on the DC-SIGN tetramer
showing that the compound can reach across to adjacent binding sites.
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